Subcutaneous recombinant interferon-β-1a (Rebif®): A review of its use in relapsing-remitting multiple sclerosis

Drugs

Volumn 65, Issue 9, 2005, Pages 1295-1312

  Murdoch, David ^a   Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Interferon 1a; Multiple sclerosis; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NEFAZODONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE REACTION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; REVIEW; RISK BENEFIT ANALYSIS; SKIN NECROSIS; STATISTICAL SIGNIFICANCE;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 22744432518     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565090-00010     Document Type: Review

References (53)

1. Khan O, Zabad R, Caon C, et al. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16 (8): 563-78
2. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: an overview. Neurology 2002 Sep 24; 59 (6 Suppl. 3): S1-33
3. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan 22; 58 (2): 169-78
4. Corboy JR, Goodin DS, Frohman EM. Disease-modifying therapies for multiple sclerosis. Curr Treat Options Neurol 2003 Jan; 5 (1): 35-54
5. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Technology Appraisal Guidance No. 32. London: National Institute for Clinical Excellence, 2002 Jan
6. Polman CH, Uitdehaag BMJ. Drug treatment of multiple sclerosis. BMJ 2000 Aug 19; 321: 490-4
7. Fernandez O. Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use? CNS Drugs 2004; 18 (15): 1057-70
8. Freedman MS, Blumhardt LD, Brochet B, et al. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler 2002 Feb; 8 (1): 19-23
9. Biogen Idec Inc., Elan Pharmaceuticals. Important drug warning: voluntary suspension of Tysabri (natalizumab) marketing [online]. Available from URL: http://www.tysabri.com [Accessed 2005 Mar 22]
10. Serono, Inc. Rebif (interferon-beta-1a) sc injection: prescribing information. Rockland (MA): Serono, Inc., 2004
11. Liberati AM, Horisberger MA, Palmisano L, et al. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. J Interferon Res 1992; 12 (5): 329-36
12. Liberati AM, Garofani P, De Angelis V, et al. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res 1994; 14 (2): 61-9
13. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 Apr 23; 58 (8 Suppl. 4): S3-9
14. Zhang J, Hutton G, Zang Y. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther 2002 Dec; 24 (12): 1998-2021
15. Wagstaff AJ, Goa KL. Recombinant interferon-β-1a: a review of its therapeutic efficacy in relapsing-remitting multiple sclerosis. Biodrugs 1998; 10 (6): 471-94
16. Rothuizen LE, Buclin T, Spertini F, et al. Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 1999 Sep 1; 99 (1): 131-41
17. Buraglio M, Trinchard-Lugan I, Munafo A, et al. Recombinant human interferon-β-1a (Rebif) vs recombinant interferon-β-1b (Betaseron) in healthy volunteers: a pharmacodynamic and tolerability study. Clin Drug Invest 1999; 18 (1): 27-34
18. Salmon P, Le Cotonnec JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 1996 Oct; 16 (10): 759-64
19. Munafo A, Trinchard-Lugan I, Nguyen TX, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998 Mar; 5 (2): 187-93
20. Buchwalder PA, Buclin T, Trinchard I, et al. Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers. J Interferon Cytokine Res 2000 Oct; 20 (10): 857-66
21. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001 Oct 1; 256 (1-2): 141-52
22. Deisenhammer F, Mayringer I, Harvey J, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology 2000 Jun 13; 54 (11): 2055-60
23. Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001 Oct; 50 (4): 443-51
24. Brescia Morra V, Coppola G, Orefice G, et al. Interferon-β treatment decreased cholesterol plasma levels in multiple sclerosis patients. Neurology 2004 Mar; 62 Pt 1: 829-30
25. Wandinger KP, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003 Jun 14; 361: 2036-43
26. Sharief MK, Semra YK. Down-regulation of survivin expression in T lymphocytes after interferon beta-1a treatment in patients with multiple sclerosis. Arch Neurol 2002 Jul; 59 (7):1115-21
27. Harzheim M, Stepien-Mering M, Schroder R, et al. The expression of microfilament-associated cell-cell contacts in brain endothelial cells is modified by IFN-β1a (Rebif). J Interferon Cytokine Res 2004 Dec; 24 (12): 711-6
28. Hong J, Tejada-Simon MV, Rivera VM, et al. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler 2002 May; 8 (3): 237-42
29. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001 Aug; 58 (8): 1297-8
30. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 2003 Feb 25; 60 (4): 634-9
31. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000 Nov; 48 (5): 706-12
32. Bertolotto A, Deisenhammer F, Gallo P, et al. Immunogenicity of interferon beta: differences among products. J Neurol 2004 Jun; 251 Suppl. 2: ll/15-24
33. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-β) antibodies in interferon-β1a- and interferon-β1b-treated multiple sclerosis patients: prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur Cytokine Netw 2001 Mar; 12 (1): 56-61
34. Vartanian TK, Zamvil SS, Fox E, et al. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004 Dec 14; 63 (11 Suppl. 5): S42-9
35. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002 Nov 26; 59 (10): 1496-506
36. Paty D. Long-term observational efficacy and safety follow-up of the PRISMS cohort [abstract no. P555 plus poster]. 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 2003 Sep 17-20; Milan
37. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis: PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 352 (9139): 1498-504
38. Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing MS: the EVIDENCE study. Arch Neurol 2005 May; 62 (5): 785-92
39. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001 Jun 26; 56 (12): 1628-36
40. Sorensen PS, Ross C, Clemmesen KJ, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 Oct 11; 362 (9391): 1184-91
41. Li D, Abdalla JA. Long-term observational follow-up of the PRISMS cohort: analyses of MRI BOD shows benefit of high dose, high frequency IFNbeta-1a (Rebif) [abstract no. P02.118]. Neurology 2004 Apr; 62 (7 Suppl. 5): A153-4
42. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999 Aug; 46 (2): 197-206
43. Francis GS, Grumser Y, Alteri E, et al. Heptatic reactions during treatment of multiple sclerosis with inteferon-β-1a: incidence and clinical significance. Drug Saf 2003; 26 (11): 815-27
44. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004 Jun; 10 (3): 298-301
45. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between the three products. Neurology 2004 Feb 24; 62 (4): 628-31
46. Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004 Nov; 251 (11): 1297-303
47. Rieckmann P, O'Connor P, Francis GS, et al. Haematological effects of interferon-β-1a (Rebif) therapy in multiple sclerosis. Drug Saf 2004; 27 (10): 745-56
48. Patten SB, Metz LM. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001 Aug; 7 (4): 243-8
49. Sandberg-Wollheim M, Bever C, Carter J, et al. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis: the EVIDENCE study. J Neurol 2005 Jan; 252 (1): 8-13
50. Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004 Sep; 251 Suppl. 5: v/42-9
51. Lepen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-β-1a in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Clin Drug Invest 2003; 23 (9): 571-81
52. Beresniak A., Coyle P, Vollmer T, et al. Cost-benefit and cost-effectiveness analyses of interferon beta-1a therapies for multiple sclerosis [abstract no. P414 plus poster]. 13th Annual Meeting of the European Neurological Society; 2003 Jun 14-18; Istanbul
53. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002 Oct 28; 162 (19): 2161-9